Drug Trial Radar · NCT02422719
Radotinib as 3rd or Later Line Therapy in CP-CML
Last checked: Nov 19, 2026Latest source record: May 11, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
73
Planned (sponsor's estimate)
Start
Apr 2015
Primary completion
Mar 2019
Study completion Mar 2019
Sponsor
- Lead sponsor
- Ulsan University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 21, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether radotinib is effective and safe for patients with chronic myeloid leukemia, chronic phase who are intolerable or resistant to prior 2 or more tyrosine kinase inhibitors.
Conditions
- Chronic Myeloid Leukemia
Interventions
RadotinibDrug
Radotinib 400mg bid
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Major cytogenetic responseTime frame: by 12 months after radotinib treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ulsan University Hospital
Ulsan, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.